Related references
Note: Only part of the references are listed.New Obesity Indices and Adipokines in Normotensive Patients and Patients With Hypertension Comparative Pilot Analysis
Mariusz Stepien et al.
ANGIOLOGY (2014)
Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia
Krzysztof Łabuzek et al.
Pharmacological Reports (2014)
Adipokines in obesity
Viviane de Oliveira Leal et al.
CLINICA CHIMICA ACTA (2013)
Metformin in Obese Children and Adolescents: The MOCA Trial
D. Kendall et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Resistin expression correlates with steatohepatitis in morbidly obese patients
Claire R. Edwards et al.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2013)
Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes
Nikolaos P. E. Kadoglou et al.
ACTA DIABETOLOGICA (2012)
Telmisartan at 80 mg/Day Increases High-Molecular-Weight Adiponectin Levels and Improves Insulin Resistance in Diabetic Patients
Hiroko Mori et al.
ADVANCES IN THERAPY (2012)
Adipocyte-specific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice
Frederique Yiannikouris et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2012)
Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet
Julio Cesar Fraulob et al.
CLINICAL SCIENCE (2012)
Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome
A. P. Agouridis et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2012)
The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial
Maria Lola Evia-Viscarra et al.
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM (2012)
Telmisartan Improves Cardiometabolic Profile in Obese Patients with Arterial Hypertension
Malgorzata Kubik et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2012)
Correlation between mesenteric fat thickness and serum apolipoproteins in patients with peripheral arterial occlusive disease
Apostolos Perelas et al.
LIPIDS IN HEALTH AND DISEASE (2012)
Role of Subcutaneous Adipose Tissue in Metabolic Complications of Obesity
Nicola Abate et al.
METABOLIC SYNDROME AND RELATED DISORDERS (2012)
Serum adiponectin level is correlated with the size of HDL and LDL particles determined by high performance liquid chromatography
Kazumi Tsubakio-Yamamoto et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2012)
Chemerin and Adiponectin Contribute Reciprocally to Metabolic Syndrome
Sang Hui Chu et al.
PLOS ONE (2012)
Adipose tissue dysregulation and reduced insulin sensitivity in non-obese individuals with enlarged abdominal adipose cells
Ann Hammarstedt et al.
DIABETOLOGY & METABOLIC SYNDROME (2012)
Omentin as a novel biomarker of metabolic risk factors
Rei Shibata et al.
DIABETOLOGY & METABOLIC SYNDROME (2012)
New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women
Teresa Auguet et al.
BMC MEDICAL GENETICS (2011)
Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis
Zubair Shah et al.
CIRCULATION (2011)
Serum amyloid A in atherosclerosis
Victoria L. King et al.
CURRENT OPINION IN LIPIDOLOGY (2011)
“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses
Dimitri P. Mikhailidis et al.
Current Vascular Pharmacology (2011)
“European Panel On Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary
Dimitri P. Mikhailidis et al.
Current Vascular Pharmacology (2011)
Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta-analysis and systemic review
Yu-Hung Chang et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2011)
Plasma proteomic analysis in obese and overweight prepubertal children
Zoi Galata et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2011)
Serum Resistin Concentrations are Higher in Human Obesity but Independent from Insulin Resistance
M. Owecki et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2011)
Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus
Niki Katsiki et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2011)
Comparison between orlistat plus L-carnitine and orlistat alone on inflammation parameters in obese diabetic patients
Giuseppe Derosa et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2011)
Liraglutide Prevents Hypoadiponectinemia-Induced Insulin Resistance and Alterations of Gene Expression Involved in Glucose and Lipid Metabolism
Ling Li et al.
MOLECULAR MEDICINE (2011)
Adiponectin is associated with abnormal lipid profile and coronary microvascular dysfunction in patients with dilated cardiomyopathy without overt heart failure
Daniela Giannessi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2011)
Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes
Padma Sathyanarayana et al.
OBESITY (2011)
In vitro and in vivo Effects of Metformin on Human Adipose Tissue Adiponectin
Alessandra Zulian et al.
OBESITY FACTS (2011)
Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management
A. P. van de Woestijne et al.
OBESITY REVIEWS (2011)
Visfatin Is Regulated by Rosiglitazone in Type 2 Diabetes Mellitus and Influenced by NFκB and JNK in Human Abdominal Subcutaneous Adipocytes
Kirsty C. McGee et al.
PLOS ONE (2011)
Metformin restores the correlation between serum-oxidized LDL and leptin levels in type 2 diabetic patients
Manouchehr Nakhjavani et al.
REDOX REPORT (2011)
Adipokines in inflammation and metabolic disease
Noriyuki Ouchi et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Apelin, diabetes, and obesity
Isabelle Castan-Laurell et al.
ENDOCRINE (2011)
Adipose Tissue-Specific Regulation of Angiotensinogen in Obese Humans and Mice: Impact of Nutritional Status and Adipocyte Hypertrophy
Shintaro Yasue et al.
AMERICAN JOURNAL OF HYPERTENSION (2010)
Effects of Rimonabant, as Monotherapy and in Combination With Fenofibrate or Ezetimibe, on Plasma Adipokine Levels: A Pilot Study
Matilda Florentin et al.
ANGIOLOGY (2010)
Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes
Manfredi Rizzo et al.
ANGIOLOGY (2010)
CNS leptin and insulin action in the control of energy homeostasis
Bengt F. Belgardt et al.
YEAR IN DIABETES AND OBESITY (2010)
Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes
Alfonso Bellia et al.
ATHEROSCLEROSIS (2010)
Effects of Combination Lipid Therapy in the Management of Patients With Type 2 Diabetes Mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
Andrew M. Tonkin et al.
CIRCULATION (2010)
Beneficial Effect of Combination Therapy Comprising Angiotensin II Receptor Blocker Plus Calcium Channel Blocker on Plasma Adiponectin Levels
Yukiko Inoue et al.
CLINICAL AND EXPERIMENTAL HYPERTENSION (2010)
Effect of Rimonabant on Glycemic Control in Insulin-Treated Type 2 Diabetes: The ARPEGGIO Trial
Priscilla A. Hollander et al.
DIABETES CARE (2010)
Effect of Ezetimibe on Hepatic Fat, Inflammatory Markers, and Apolipoprotein B-100 Kinetics in Insulin-Resistant Obese Subjects on a Weight Loss Diet
Dick C. Chan et al.
DIABETES CARE (2010)
Alterations of Insulin Resistance and the Serum Adiponectin Level in Patients with Type 2 Diabetes Mellitus Under the Usual Antihypertensive Dosage of Telmisartan Treatment
Yoshinobu Fuke et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2010)
Association between serum amyloid A and obesity: a meta-analysis and systematic review
Yulan Zhao et al.
INFLAMMATION RESEARCH (2010)
Effects of Ezetimibe Add-on to Statin Therapy on Adipokine Production in Patients With Metabolic Syndrome and Stable Vascular Disease
Milan Gupta et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2010)
Valsartan Increases Circulating Adiponectin Levels without Changing HOMA-IR in Patients with Type 2 Diabetes Mellitus and Hypertension
J-M Lee et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2010)
Adipose tissue as an endocrine organ
Sandra Galic et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
Association between serum vaspin concentrations and visceral adipose tissue in Korean subjects
Hye Mi Chang et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2010)
Effects of Weight Reduction on Serum Vaspin Concentrations in Obese Subjects: Modification by Insulin Resistance
Hye M. Chang et al.
OBESITY (2010)
Effect of Combination Nicotinic Acid and Gemfibrozil Treatment on Intermediate Density Lipoprotein, and Subclasses of Low Density Lipoprotein and High Density Lipoprotein in Patients With Combined Hyperlipidemia
H. Robert Superko et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Effect of Rimonabant on the High-Triglyceride/Low-HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat The ADAGIO-Lipids Trial
Jean-Pierre Despres et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance
Axel Linke et al.
ATHEROSCLEROSIS (2009)
Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression
Le Thi Kim Chung et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Implications of crosstalk between leptin and insulin signaling during the development of diet-induced obesity
Christopher D. Morrison et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2009)
Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes
M. von Eynatten et al.
CLINICAL ENDOCRINOLOGY (2009)
Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes
M. van Hoek et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
The Endocannabinoid System: A Promising Target for the Management of Type 2 Diabetes
Andre J. Scheen
CURRENT PROTEIN & PEPTIDE SCIENCE (2009)
Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis
Yun Hu et al.
DIABETES & VASCULAR DISEASE RESEARCH (2009)
Circulating Levels of Resistin and Risk of Type 2 Diabetes in Men and Women: Results From Two Prospective Cohorts
Brian H. Chen et al.
DIABETES CARE (2009)
Cross-Sectional Associations Between Abdominal and Thoracic Adipose Tissue Compartments and Adiponectin and Resistin in the Framingham Heart Study
Shilpa H. Jain et al.
DIABETES CARE (2009)
Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual β-cell function: results from the PioSwitch Study
C. Hohberg et al.
DIABETES OBESITY & METABOLISM (2009)
Leptin Augments the Acute Suppressive Effects of Insulin on Hepatic Very Low-Density Lipoprotein Production in Rats
Wan Huang et al.
ENDOCRINOLOGY (2009)
Zinc-α2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue
F-Y Gong et al.
INTERNATIONAL JOURNAL OF OBESITY (2009)
Effects of Atorvastatin on Nuclear Magnetic Resonance-Defined Lipoprotein Subclasses and Inflammatory Markers in Patients with Hypercholesterolemia
Katsunori Ikewaki et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2009)
Effects of Telmisartan Therapy on Metabolic Profiles and Serum High Molecular Weight (HMW)-Adiponectin Level in Japanese Male Hypertensive Subjects with Abdominal Obesity
Naoko Komiya et al.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2009)
Insulin-Stimulated Increase in Serum Leptin Levels Precedes and Correlates with Weight Gain during Insulin Therapy in Type 2 Diabetes
Anne-Marie Aas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Adiponectin and energy homeostasis: consensus and controversy
Sami Dridi et al.
JOURNAL OF NUTRITIONAL BIOCHEMISTRY (2009)
Effect of orlistat on the total ghrelin and leptin levels in obese patients
Y. Ozkan et al.
JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY (2009)
Effect of diet-induced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome
M. V. Heinonen et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2009)
Effect of Atorvastatin Versus Rosuvastatin on Levels of Serum Lipids, Inflammatory Markers and Adiponectin in Patients with Hypercholesterolemia
Hai-yan Qu et al.
PHARMACEUTICAL RESEARCH (2009)
Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo
Gerald F. Watts et al.
PHARMACOLOGY & THERAPEUTICS (2009)
Antiatherosclerotic and Anti-Insulin Resistance Effects of Adiponectin: Basic and Clinical Studies
Seung Hwan Han et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2009)
Effects of Rosuvastatin and Colestimide on Metabolic Parameters and Urinary Monocyte Chemoattractant Protein-1 in Type 2 Diabetic Patients with Hyperlipidemia
Kohzo Takebayashi et al.
SOUTHERN MEDICAL JOURNAL (2009)
Effects of Telmisartan and Ramipril on Adiponectin and Blood Pressure in Patients with Type 2 Diabetes
Christian Delles et al.
AMERICAN JOURNAL OF HYPERTENSION (2008)
Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages
Kazumi Tsubakio-Yamamoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure
Yumi Miyashita et al.
CARDIOVASCULAR DIABETOLOGY (2008)
Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men
Ioanna Gouni-Berthold et al.
CLINICAL ENDOCRINOLOGY (2008)
Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease
Helene von Bibra et al.
DIABETES & VASCULAR DISEASE RESEARCH (2008)
SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes
Julio Rosenstock et al.
DIABETES CARE (2008)
Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus
Hae Jin Kim et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Hyperleptinemia as a Robust Risk Factor of Coronary Artery Disease and Metabolic Syndrome in Type 2 Diabetic Patients
Soo-Kyung Kim et al.
ENDOCRINE JOURNAL (2008)
Obesity and Dyslipidemia
Remco Franssen et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2008)
The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS
Ulrich Kintscher
EUROPEAN HEART JOURNAL (2008)
The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia
E. S. Nakou et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Effect of obesity on the plasma lipoprotein subclass profile in normoglycemic and normolipidemic men and women
F. Magkos et al.
INTERNATIONAL JOURNAL OF OBESITY (2008)
Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes
C-H. Chu et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2008)
Gene Therapy for Diabetes: Metabolic Effects of Helper-dependent Adenoviral Exendin 4 Expression in a Diet-induced Obesity Mouse Model
Susan L. Samson et al.
MOLECULAR THERAPY (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones
Ozen Oz et al.
ENDOCRINE (2008)
Serum vaspin concentrations in human obesity and type 2 diabetes
Byung-Soo You et al.
DIABETES (2008)
Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training
Matthias Blueher et al.
DIABETES CARE (2007)
Adiponectin deficiency suppresses ApoA-I synthesis in ABCA1 expression and the liver
Hiroyuki Oku et al.
FEBS LETTERS (2007)
Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus
Tetsuya Teranishi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2007)
Serum concentration of visfatin in obese women
Barbara Zahorska-Markiewicz et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2007)
Extended-release niacin raises adiponectin and leptin
Sabine Westphal et al.
ATHEROSCLEROSIS (2007)
Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus
M. Bajaj et al.
DIABETOLOGIA (2007)
Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver
Fumihiko Matsuura et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass
Nora Kloeting et al.
CELL METABOLISM (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia
C. Otto et al.
ACTA DIABETOLOGICA (2007)
The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates
Manfredi Rizzo et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Weight gain in type 2 diabetes mellitus
A. N. Jacob et al.
DIABETES OBESITY & METABOLISM (2007)
Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin
Giuseppe Derosa et al.
HYPERTENSION RESEARCH (2007)
Metabolic complications of obesity: inflated or inflamed?
Manisha Chandalia et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2007)
Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level
Aki Hiuge et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity?
C. Bulcao et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2007)
The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes
M. Rizzo et al.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES (2007)
Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus
Pramod Kumar Sharma et al.
CLINICAL ENDOCRINOLOGY (2006)
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
Andre J. Scheen et al.
LANCET (2006)
Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects
Timothy E. Graham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial
JD Otvos et al.
CIRCULATION (2006)
Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-α levels in Type 2 diabetic patients:: a randomized study
H Shimizu et al.
DIABETIC MEDICINE (2006)
Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus
CS Chu et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial
F Pi-Sunyer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Obesity and the role of adipose tissue in inflammation and metabolism
ASG Martin et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2006)
Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia
W. H. Yin et al.
DIABETES & METABOLISM (2006)
The clinical relevance of low-density-lipoproteins size modulation by statins
Manfredi Rizzo et al.
CARDIOVASCULAR DRUGS AND THERAPY (2006)
Leptin: A promising therapeutic target with pleiotropic action besides body weight regulation
Kosmas I. Paraskevas et al.
CURRENT DRUG TARGETS (2006)
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
JP Despres et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes
Q Yang et al.
NATURE (2005)
Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes
KK Koh et al.
HYPERTENSION (2005)
The influence of adiponectin gene polymorphism on the rosightazone response in patients with type 2 diabetes
ES Kang et al.
DIABETES CARE (2005)
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:: 1-year experience from the RIO-Europe study
LF Van Gaal et al.
LANCET (2005)
Apelin, a newly identified adipokine up-regulated by insulin and obesity
J Boucher et al.
ENDOCRINOLOGY (2005)
Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes
M von Eynatten et al.
DIABETES CARE (2005)
Serum amyloid A:: production by human white adipocyte and regulation by obesity and nutrition
C Poitou et al.
DIABETOLOGIA (2005)
Adipocytokines and VLDL metabolism - Independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics?
TWK Ng et al.
DIABETES (2005)
Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome
ME Trujillo et al.
JOURNAL OF INTERNAL MEDICINE (2005)
被撤回的出版物: Visfatin: A protein secreted by visceral fat that mimics the effects of insulin (Retracted article, see vol 318, pg 565, 2007)
A Fukuhara et al.
SCIENCE (2005)
Intracerebroventricular leptin regulates hepatic cholesterol metabolism
S VanPatten et al.
BIOCHEMICAL JOURNAL (2004)
Transcriptional control of apolipoprotein A-I gene expression in diabetes
AD Mooradian et al.
DIABETES (2004)
Leptin effects on pancreatic β-cell gene expression and function
J Seufert
DIABETES (2004)
Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1
LJ Ma et al.
DIABETES (2004)
Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients
Y Miyazaki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients
M Bajaj et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease
K Ogasawara et al.
ATHEROSCLEROSIS (2004)
Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients
E Ascer et al.
ATHEROSCLEROSIS (2004)
Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis
KD Niswender et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2004)
Triglycerides induce leptin resistance at the blood-brain barrier
WA Banks et al.
DIABETES (2004)
Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia
MJ Caslake et al.
ATHEROSCLEROSIS (2003)
Adiponectin: More than just another fat cell hormone?
M Chandran et al.
DIABETES CARE (2003)
Insulin-dependent modulation of plasma ghrelin and leptin concentrations is less pronounced in type 2 diabetic patients
C Anderwald et al.
DIABETES (2003)
Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects
M Faraj et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Resistin and type 2 diabetes: Regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes
PG McTernan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes
JQ Pan et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2002)
Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes
J Pan et al.
DIABETES OBESITY & METABOLISM (2002)
Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity
EL Air et al.
NATURE MEDICINE (2002)
Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes
M Fasshauer et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue
CM Halleux et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation
F Massiéra et al.
FASEB JOURNAL (2001)
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
T Yamauchi et al.
NATURE MEDICINE (2001)
The hormone resistin links obesity to diabetes
CM Steppan et al.
NATURE (2001)
Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients
K Hotta et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Bezafibrate reduces blood glucose in type 2 diabetes mellitus
S Ogawa et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2000)
The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in Type 2 diabetic patients
D Worm et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2000)
Share Paper
